Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRV

- PMLiVE

Takeda’s dengue vaccine seems safe with no prior virus exposure

Appears unaffected by serious safety issue affecting Sanofi rival

- PMLiVE

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Results at six months demonstrated 75% of patients were progression-free

- PMLiVE

Aveo’s tivozanib is knocked back by FDA once again

Company says it will delay any regulatory filing until first quarter next year

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

MD Anderson exec Stephen Hahn to be nominated FDA commissioner

US President Trump scouts well-known oncology expert to lead agency

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

- PMLiVE

Dupixent gains can’t keep Sanofi on a growth track

Reports fall in Q3 sales despite growth of immunology drug

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

- PMLiVE

Vertex scores FDA approval for CF triple therapy Trikafta

Decision comes only a few months after therapy was filed

Roche Basel Switzerland

Roche scores another FDA approval for Xofluza

Expands use to patients at high risk of flu-related complications

- PMLiVE

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Head-to-head trial with rival Eylea could boost sales

- PMLiVE

Gilead builds case for Descovy PrEP after FDA approval

Reported statistically significant improvements in kidney function

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links